Ellen Ritchie is an Oncology physician affiliated with Cornell University. OpenAlex indexes 300 publications with 8,172 citations (h-index 41); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 East 70th Street, Starr 341
New York, NY 10021
Telephone
212-746-6264Registry record last updated 16 Sept 2011.
Clinical trials
- CPX-351+GO in Subjects 55 Years Old, or Older, With AML
Sponsor: Weill Medical College of Cornell University
- Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia
Sponsor: Weill Medical College of Cornell University
- Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20241 payment
- ABBVIE INC.Program year20241 payment
- NOVARTIS PHARMACEUTICALS CORPORATIONProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
66%Kinase inhibitor39.2%Jakafi80%Sprycel11%Imatinib Mesylate9%Part D<11 patientsAntimetabolite9.7%Hydroxyurea100%Part D≥16 patients+ 4 more classes in this area
Anti-infectives
18.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8%Valacyclovir100%Part D≥12 patientsFluoroquinolone Antibacterial4%Levofloxacin100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
4.2%Factor Xa inhibitor4.2%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera
New England Journal of Medicine
2024 - Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Devereux, MD
Cornell University
Thomas Walsh, MD
Cornell University
Cora Sternberg, MD
Cornell University
George Alexopoulos, MD
Cornell University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”